A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

Phase 3

Completed

• Conditions: Parkinson's Disease

• Registration Number: NCT00139867
• Lead Sponsor: UCB Pharma

Brief Summary

The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson's disease.

Detailed Description

See approved Package Insert for Adverse Event information.

Study Timeline

• Study Start: 2004-01
• Primary Completion: 2004-05
• Study Completion: 2004-05
• Study First Submitted: 2005-08-29
• Study First Submitted QC: 2005-08-30
• Study First Posted: 2005-08-31
• Status Verified: 2009-09
• Last Update Submitted: 2014-10-17
• Last Update Posted: 2014-10-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Stable Parkinson's Disease

Exclusion Criteria

• Not using carbidopa/levodopa tablets

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Trial Locations

Locations (1)

Schwarz; 🇺🇸 Milwaukee, Wisconsin, United States